Evidence level: B
「严重度越高、放大越强」听上去像常识,其实是一个从未被检验过的形状假设——而且它默认的那种直线,恰恰是生理系统最不常给出的一种。
正文
前两篇把「病理放大」拆到了两处:先问它是不是真的(尺度与假象),再问它长在哪儿(局部还是全身)。剩下最后一问:它随严重度怎么变。这个问法看似温和,其实换了一整套逻辑——前面的问题是「有没有」,这里是「形状」。
形状问题有个特殊陷阱:它默认了「严重度」是一根轴。但临床上至少有四种东西被叫作严重度,它们互不换算。疼痛 VAS/NRS 是主观报告,是序数量表而非等距尺,VAS 与 Likert 的响应关系本身是非线性的(PMID 12814613),而单维疼痛工具的重测信度与反应度证据质量普遍偏低,该领域 31 项研究里多数未达 COSMIN 方法学标准(PMID 34999588);病程是时间累积,方向可能相反(久病既可能适应,也可能中枢敏化);CRP/IL-6 是全身炎症活性,与局部疼痛并不同步——非特异性腰痛的系统综述结论很干脆:hs-CRP 与腰痛不相关,且证据不足以把生物标志物与疼痛严重度或活动状态联系起来(PMID 37195364);类风湿关节炎中炎症指标只解释 22%–27% 的疼痛方差(PMID 39380043);慢性紧张型头痛患者用非甾体药后疼痛显著下降,TNF-α、IL-1、IL-6 却一动不动(PMID 28293317)。中枢敏化指标(QST) 又是另一套尺度。四根轴若给出不同斜率,「剂量-反应」四个字就没有单一所指,讨论必然各说各话。这四根轴自身的精度也不齐:CRP 的个体内变异显著大于胆固醇(ICC 0.62),基线最高三分位者有一半在随访时落入不一致类别,基线超过 3 mg/L 的人里 69% 后来降到更低风险档(PMID 22846611)——一根自己就会跳动的轴,撑不起精密的斜率估计。
第二个陷阱更硬:「放大倍数」是个比值,而比值在分母小的时候会自己长出形状。 若把响应写成「患者组变化 ÷ 健康组变化」,健康组响应接近零时,分母既小又抖,比值于是爆炸且方差极大——低严重度那一端恰恰分母最不稳,曲线末端自然翘起。这不是生理,是除法。有一份干净的实证先例:一项 304 例的骨质疏松研究里,用百分比变化做结局时,「低 BMI 患者反应更强」显著成立;换成绝对变化后,这个关联彻底消失(r = −0.064,p = 0.267),作者直接判定百分比指标是数学伪影(PMID 42203994)。同一批数据、两种度量、两个结论。
第三个陷阱:直线是最不该默认的形状。 生理系统的剂量-反应通常先饱和再平台;阿托品近视防控的剂量-反应 meta 分析给出的正是阈值效应而非线性(PMID 42070753),他克莫司浓度与急性排斥也是明确非线性(PMID 31333109)。中医自己也不认为它单调,《素问·六微旨大论》讲「亢则害,承乃制」——过头会反噬,这是倒 U,不是直线。
第四层要说句公道话:基线-变化的相关里确实有一份来自数学耦合(基线与变化共享误差项),但这条批评有边界——耦合在个体分数层面成立,组水平统计量并不受其影响(PMID 21803544)。所以在本主题里,耦合只是个体层面的威胁;组水平真正的威胁是分母不稳与回归到均值,而非耦合本身。
第五层,严重度高的人不是「同一种人的加重版」。严重度与用药、共病、年龄高度共线,这就是适应证混杂——倾向评分也治不了没测到的那部分(PMID 24217206)。可用的探针有三件:负对照结局(PMID 40838594;PMID 38619297)、E-value 量化「需要多强的未测混杂才能解释掉」(PMID 28693043),以及警惕反向的过度校正——校正中介会偏离零而不是趋零(PMID 42821507)。把严重度二分成「重/轻」还会额外损失功效并留下残余混杂(PMID 16217841)。
把这些落成一个能执行的方案,有四条硬约束。同一人做接地/非接地交叉,用配对内差值当响应量,让每个人的基线和用药史自己给自己当对照——这是唯一能同时削掉组间基线和回归到均值的做法。严重度按连续变量入模型,除主效应外只放「严重度 × 接地」一个交互项,不预设分组切点。四根轴各自跑一遍,把四条斜率与四条 95%CI 并排放在一张表里,同向才叫剂量-反应,不同向就老实写「不同严重度定义下不可比」。曲线用限制性样条,结点数预先定死(3–4 个),报拟合优度与形状检验,不用「斜率显著」代替「形状是什么」。加一个健康基线组不为比较放大倍数,只为定位「零响应点」在哪儿——有了零点,倍数才有分母。
所以判决只有三句。一是剂量轴先选一根、预注册,别在同一篇里四条轴混着讲。二是绝对变化作主结局,倍数只作敏感性分析,且必须同时报分母的变异。三是形状先验三选一(单调/阈值/平台),用限制性样条拟合后比拟合优度,而不是只报斜率符号。
易学落点在《素问·通评虚实论》:「邪气盛则实,精气夺则虚。」同一个人症状加重,可能是邪增,也可能是正减——两条路在「严重度」这一个数字上长得一模一样,但对外部干预的响应曲线方向相反。所以传统模型从来不把剂量-反应设成直线:它设的是「实者泻之、虚者补之」的分岔。单调是现代人替它加上去的。
证据与局限
已验证: 炎症标志物与疼痛严重度的关联在不同病种中强度差异极大,且 hs-CRP 与腰痛不相关(PMID 37195364);炎症仅解释 RA 疼痛方差的 22%–27%(PMID 39380043);镇痛药可显著降低疼痛而不改变 TNF-α/IL-1/IL-6(PMID 28293317);CRP 个体内变异显著大于胆固醇(ICC 0.62,最高三分位 51% 随访时落入不一致类别,PMID 22846611);百分比变化可系统制造出「低基线反应更强」的伪信号(PMID 42203994);阿托品剂量-反应呈阈值型(PMID 42070753)。
部分验证: 数学耦合在个体层面成立而组水平不受影响(PMID 21803544),这限定了耦合批评的适用范围;单维疼痛量表的测量学证据质量偏低(PMID 34999588),使「严重度」这条轴本身精度可疑;负对照结局与 E-value 可探测未测混杂(PMID 40838594;PMID 28693043),但均未在接地-阻抗场景中应用过。
待验证: 同一批数据在 VAS、病程、CRP、QST 四根轴上的剂量-反应斜率是否同向;「放大倍数」在低严重度分位是否系统性偏高(分母效应);限制性样条拟合下曲线形状更接近单调、阈值还是平台。
相关阅读
- 「病人反应更大」这句话,先要问是哪把尺子量的
- 「近」是什么意思:接地-穴位阻抗的经络特异性
- 你要找的那个中介,可能就是这个结局本身
- 吉地「舒适感」与接地生理指标的关联验证
- 研究池子:环境-生命频率接口
证据等级: B
参考文献: PMID 37195364, PMID 39380043, PMID 28293317, PMID 22846611, PMID 42203994, PMID 42070753, PMID 34999588, PMID 12814613, PMID 21803544, PMID 31333109, PMID 24217206, PMID 40838594, PMID 38619297, PMID 28693043, PMID 42821507, PMID 16217841
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
\”Greater Severity Equals Greater Reaction\”: An Unverified Straight Line and Four Incommensurable Measures of Severity
Evidence level: B
“Higher severity implies greater amplification” sounds like common sense, but it is actually an untested shape assumption—one that defaults to a straight line, which is precisely the form physiological systems rarely produce.
Main Text
The previous two articles dissected “pathological amplification” into two parts: first, whether it exists at all (scale vs. illusion), and second, where it occurs (local vs. systemic). The final question remains: How does it change with severity. This framing, while seemingly gentle, shifts the entire logic—previous questions asked “does it exist,” whereas this asks about “shape.”
The shape question carries a specific trap: it defaults to treating “severity” as a single axis. However, clinically, there are at least four distinct constructs labeled “severity,” which are not interchangeable. Pain VAS/NRS is a subjective report using an ordinal scale rather than an interval scale; the response relationship between VAS and Likert scales is inherently nonlinear (PMID 12814613), and unidimensional pain tools generally show low reliability and responsiveness evidence quality, with most of the 31 studies in this field failing to meet COSMIN methodological standards (PMID 34999588). Duration represents time accumulation, where direction may be opposite (chronic conditions may lead to adaptation or central sensitization); CRP/IL-6 reflect systemic inflammatory activity, which is not synchronized with local pain—systematic reviews on nonspecific low back pain yield clear conclusions: hs-CRP is unrelated to low back pain, and evidence is insufficient to link biomarkers to pain severity or functional status (PMID 37195364); in rheumatoid arthritis, inflammatory markers explain only 22%–27% of pain variance (PMID 39380043); and in patients with chronic tension-type headache, pain significantly decreases after nonsteroidal anti-inflammatory drugs while TNF-α, IL-1, and IL-6 remain unchanged (PMID 28293317). Central sensitization metrics (QST) represent yet another scale. If four axes yield different slopes, the term “dose-response” lacks a single meaning, and discussions inevitably become disjointed. Furthermore, the precision of these four axes is inconsistent: CRP exhibits significantly higher within-individual variability than cholesterol (ICC 0.62); among those in the highest third at baseline, half fall into inconsistent categories at follow-up, and 69% of individuals with baseline levels exceeding 3 mg/L later drop into a lower-risk category (PMID 22846611)—an axis that fluctuates on its own cannot support precise slope estimation.
A second, harder trap is that “amplification ratio” is a quotient, and quotients explode in shape when the denominator is small. If response is written as “patient group change ÷ healthy group change,” a near-zero healthy group response creates a small, noisy denominator, causing the ratio to explode with extreme variance—this instability occurs precisely at the low-severity end, naturally curving upward at the tail. This is not physiology; it is division. A clean empirical precedent exists: in a study of 304 osteoporosis patients, using percentage change as the outcome showed that “lower BMI patients responded more strongly” significantly; however, when switching to absolute change, this association vanished entirely (r = −0.064, p = 0.267), with authors directly concluding that percentage metrics are mathematical artifacts (PMID 42203994). Same data, two metrics, two conclusions.
The third trap is that the straight line is the least appropriate default shape. Physiological dose-response curves typically saturate before plateauing; a meta-analysis of atropine myopia prevention dose-response yielded a threshold effect rather than linearity (PMID 42070753), and tacrolimus concentration versus acute rejection is explicitly nonlinear (PMID 31333109). Traditional Chinese Medicine itself does not view it as monotonic; the Su Wen · Liu Wei Zhi Da Lun states “Excess leads to harm, and counter-regulation controls it”—overshoot leads to backlash, forming an inverted U, not a straight line.
On the fourth layer, we must speak fairly: there is indeed some mathematical coupling in the correlation between baseline and change (sharing an error term at the individual score level), but this critique has boundaries—coupling holds at the individual score level but does not affect group-level statistics (PMID 21803544). Therefore, in this topic, coupling poses a threat only at the individual level; the genuine threats at the group level are denominator instability and regression to the mean, not coupling itself.
On the fifth layer, individuals with high severity are not simply “heavier versions of the same person.” Severity is highly collinear with medication, comorbidities, and age, constituting indication confounding—propensity scores cannot fix unmeasured portions (PMID 24217206). Three probes are available: negative control outcomes (PMID 40838594; PMID 38619297), E-values quantifying “how strong unmeasured confounding must be to explain it away” (PMID 28693043), and vigilance against reverse overcorrection—correcting for mediators deviates from zero rather than converging to it (PMID 42821507). Dichotomizing severity into “heavy/light” additionally loses power and leaves residual confounding (PMID 16217841).
To operationalize this, four hard constraints apply. Same individual performing grounded/non-grounded crossover, using paired within-subject differences as the response variable, allows each person’s baseline and medication history to serve as their own control—this is the only method that simultaneously removes between-group baseline effects and regression to the mean. Severity entered as a continuous variable, with only a “severity × grounding” interaction term added beyond the main effect, avoiding arbitrary grouping cutoffs. Run all four axes separately, placing the four slopes and their 95% CIs side-by-side in a table; only if they align can it be called dose-response; otherwise, honestly report “incomparable under different severity definitions.” Use restricted cubic splines, fixing the number of knots in advance (3–4), reporting goodness-of-fit and shape tests, rather than substituting “significant slope” for “what the shape is.” Add a healthy baseline group not to compare amplification ratios, but to locate the “zero-response point”—only with a zero does the ratio have a denominator.
Thus, the verdict consists of three sentences. First, select one dose axis and preregister it; do not mix four axes in a single paper. Second, use absolute change as the primary outcome, treat ratios only as sensitivity analyses, and must simultaneously report denominator variability. Third, choose one of three shape priors (monotonic/threshold/plateau), fit using restricted cubic splines, and compare goodness-of-fit rather than merely reporting slope signs.
The Yijing perspective rests on the Su Wen · Tong Ping Shi Xun Lun: “When pathogenic qi is excessive, it becomes solid; when vital essence is deprived, it becomes void.” The same individual experiencing worsening symptoms may have increased pathogenic qi or decreased vital essence—two paths that grow identically on the single number of “severity,” yet produce response curves with opposite directions under external intervention. Therefore, traditional models never set dose-response as a straight line; they establish a bifurcation of “treat excess with reduction, treat void with supplementation.” Monotonicity is a modern imposition.
Evidence and Limitations
Verified: The association between inflammatory markers and pain severity varies greatly in intensity across conditions, and hs-CRP is unrelated to low back pain (PMID 37195364); inflammation explains only 22%–27% of RA pain variance (PMID 39380043); analgesics can significantly reduce pain without altering TNF-α/IL-1/IL-6 (PMID 28293317); CRP exhibits significantly higher within-individual variability than cholesterol (ICC 0.62, with 51% of highest third at baseline falling into inconsistent categories at follow-up, PMID 22846611); percentage changes can systematically generate false signals of “stronger response at low baseline” (PMID 42203994); atropine dose-response exhibits a threshold pattern (PMID 42070753).
Partially Verified: Mathematical coupling holds at the individual level but is unaffected at the group level (PMID 21803544), limiting the scope of coupling critiques; low measurement evidence quality for unidimensional pain scales (PMID 34999588) casts doubt on the precision of the “severity” axis itself; negative control outcomes and E-values can detect unmeasured confounding (PMID 40838594; PMID 28693043), but neither has been applied in grounding-impedance scenarios yet.
To Be Verified: Whether dose-response slopes across VAS, duration, CRP, and QST axes share the same direction in the same dataset; whether “amplification ratio” is systematically inflated at low severity percentiles (denominator effect); and whether curve shapes under restricted cubic spline fitting approximate monotonic, threshold, or plateau patterns more closely.
Related Reading
- Which ruler measures “greater patient response”?
- What does “near” mean: Meridian specificity in grounding-acupoint impedance
- That mediator you seek might be the outcome itself
- Validation of the association between Feng Shui “comfort” and grounding physiological indicators
- Research Pool: Environment-Life Frequency Interface
Evidence Level: B
References: PMID 37195364, PMID 39380043, PMID 28293317, PMID 22846611, PMID 42203994, PMID 42070753, PMID 34999588, PMID 12814613, PMID 21803544, PMID 31333109, PMID 24217206, PMID 40838594, PMID 38619297, PMID 28693043, PMID 42821507, PMID 16217841
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply